A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This open-label study will assess anti-tumor activity and safety of belinostat in combination
with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at
least one prior bortezomib-containing regimen. Subjects will be administered both PXD101 and
bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a 3-week cycle, for up to 8 cycles.